Havah Therapeutics Expands Expertise through Clinical Advisory Board
Havah Therapeutics, a pioneering biopharmaceutical company based in Boulder, is making headline news with the formation of its Clinical Advisory Board. This innovative company is known for developing proprietary hormonal implant therapies aimed at preventing and treating breast cancer. Leading this esteemed board is Stephen Birrell, MD, PhD, the founder of Havah Therapeutics.
A New Era for Breast Cancer Treatment
As the company progresses toward late-stage clinical studies, particularly for Ductal Carcinoma In-Situ (DCIS), the guidance and expertise of this advisory group are anticipated to be invaluable. Matthew Brewer, the CEO of Havah Therapeutics, expressed optimism about the board's contributions, noting, “The scientific and clinical guidance of this esteemed group will be invaluable as we advance our androgen targeted therapy into late-stage clinical studies.”
The Role of the Clinical Advisory Board
The Clinical Advisory Board is not just a formality; its insights will help shape the research and application of Havah’s treatments. Noted breast cancer expert Shelley Hwang, MD, MPH, highlighted the significance of their ongoing Phase 2 study, emphasizing her excitement to be part of this critical stage for the company.
Meet the Advisory Team
The Clinical Advisory Board comprises respected professionals from various fields in oncology and surgical research.
Stephen Birrell, MD, PhD (Chair) brings extensive knowledge as the founder of Havah Therapeutics and Chief Medical Officer at Wellend Health. He is also a Clinical Affiliate academic at the University of Adelaide, with a focus on women's breast hormonal health and clinical trials.
Shelley Hwang, MD, MPH serves as the Mary and Deryl Hart Distinguished Professor of Surgical Oncology and Radiology at Duke University Comprehensive Cancer Center. Her focus is on breast cancer prevention while working tirelessly to address healthcare disparities.
Seema A. Khan, MD is a professor of surgery at Northwestern University’s Feinberg School of Medicine. She leads research aimed at improving breast cancer risk assessment and developing prevention strategies for women at high risk.
Professor Wayne Tilley, PhD is the inaugural director of the Dame Roma Mitchell Cancer Research Laboratories at the University of Adelaide, contributing invaluable research on the androgen receptor and its impact on breast cancer treatments.
Innovative Research at Havah Therapeutics
Currently, Havah Therapeutics is actively involved in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (RECAST DCIS). This Phase 2 platform study aims to prevent the progression of DCIS to invasive breast cancer. Havah’s proprietary therapy, HAVAH T+Ai™, targets both the androgen and estrogen receptor pathways, a significant step in the realm of hormonal treatments.
About the HAVAH T+Ai™ Therapy
Havah's innovative therapeutic implant utilizes a combination of testosterone and anastrozole. By agonizing the androgen receptor in the breast tissue, it leverages natural hormone mechanisms to treat patients effectively while minimizing side effects. This delivery method provides three months of continuous medication, ensuring superior compliance and treatment efficacy.
About Havah Therapeutics
At the forefront of breast cancer treatment, Havah Therapeutics represents a progressive approach towards managing hormonally sensitive cancers. Their dedication to developing safe, effective treatments reflects in their advanced research and clinical trials. The addition of a Clinical Advisory Board strengthens their position significantly in the medical community and enhances their capability to deliver results in a challenging field.
Frequently Asked Questions
What is Havah Therapeutics known for?
Havah Therapeutics specializes in developing hormonal implant therapies for the prevention and treatment of breast cancers.
Who chairs the Clinical Advisory Board?
Dr. Stephen Birrell, the founder of Havah Therapeutics, chairs the Clinical Advisory Board.
What is the purpose of the RECAST DCIS study?
The RECAST DCIS study aims to evaluate prevention methods for Ductal Carcinoma In-Situ and improve treatment outcomes.
How does HAVAH T+Ai™ work?
HAVAH T+Ai™ combines testosterone and anastrozole to target androgen and estrogen pathways in breast tissue, providing a new treatment approach.
What are the qualifications of the advisory board members?
The advisory board includes leading experts in surgical oncology and cancer research, each contributing significant knowledge and insight into breast cancer treatment.
